Athens Medical C.S.A. (IATR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Athens Medical C.S.A. (IATR) has a cash flow conversion efficiency ratio of 0.029x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€3.17 Million ≈ $3.71 Million USD) by net assets (€108.78 Million ≈ $127.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Athens Medical C.S.A. for the company's overall valuation and market capitalisation.
Athens Medical C.S.A. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Athens Medical C.S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Athens Medical C.S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Athens Medical C.S.A. ranked by their cash flow conversion efficiency. Explore how high is Athens Medical C.S.A.'s earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pinago Utama Tbk Pt
JK:PNGO
|
0.094x |
|
Seoho Electric Co.Ltd
KQ:065710
|
0.039x |
|
Casa de Bolsa Finamex S.A.B. de C.V
MX:FINAMEXO
|
0.039x |
|
Acumen Pharmaceuticals Inc
NASDAQ:ABOS
|
-0.276x |
|
Zumtobel Group AG
VI:ZAG
|
0.079x |
|
Cosmax
KO:044820
|
0.073x |
|
Creditwest Faktoring AS
IS:CRDFA
|
-0.088x |
|
SAB Finance as
PR:SABFG
|
N/A |
Annual Cash Flow Conversion Efficiency for Athens Medical C.S.A. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Athens Medical C.S.A. from 2014 to 2024. View current stock price of Athens Medical C.S.A. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €108.81 Million ≈ $127.21 Million |
€46.44 Million ≈ $54.30 Million |
0.427x | +77.67% |
| 2023-12-31 | €108.77 Million ≈ $127.16 Million |
€26.13 Million ≈ $30.55 Million |
0.240x | +19904.30% |
| 2022-12-31 | €103.25 Million ≈ $120.71 Million |
€124.00K ≈ $144.97K |
0.001x | -99.22% |
| 2021-12-31 | €102.06 Million ≈ $119.32 Million |
€15.75 Million ≈ $18.41 Million |
0.154x | -66.59% |
| 2020-12-31 | €87.07 Million ≈ $101.79 Million |
€40.21 Million ≈ $47.01 Million |
0.462x | +15.96% |
| 2019-12-31 | €79.08 Million ≈ $92.46 Million |
€31.50 Million ≈ $36.82 Million |
0.398x | +42.46% |
| 2018-12-31 | €71.62 Million ≈ $83.73 Million |
€20.02 Million ≈ $23.41 Million |
0.280x | +1258.18% |
| 2017-12-31 | €63.18 Million ≈ $73.87 Million |
€-1.52 Million ≈ $-1.78 Million |
-0.024x | -114.98% |
| 2016-12-31 | €60.65 Million ≈ $70.91 Million |
€9.78 Million ≈ $11.43 Million |
0.161x | -26.39% |
| 2015-12-31 | €58.85 Million ≈ $68.80 Million |
€12.89 Million ≈ $15.07 Million |
0.219x | +350.93% |
| 2014-12-31 | €73.81 Million ≈ $86.29 Million |
€3.58 Million ≈ $4.19 Million |
0.049x | -- |
About Athens Medical C.S.A.
Athens Medical C.S.A., together with its subsidiaries, offers healthcare services in Greece and internationally. The company offers diagnosis and treatment for prostate bladder, kidney, and testicular cancer, as well as interventional cardiology, interventional electrophysiology, and pediatric cardiology; cardiac surgery; robotic surgery, including general, gynecologic, and urology services; and … Read more